Cardiac rehabilitation and exercise training has been shown to improve clinical status and outcomes in congestive heart ...
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict which coronary plaques have the potential to rupture.
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia Mapping System.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
May 23, 2016 — In a guideline update published last week, the American College of Cardiology, American Heart Association ...
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates and a greater risk of recurrent heart failure after transcatheter aortic valve replacement (TAVR).
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR meeting in Paris.
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) achieves equivalent clinical and angiographic outcomes to intravascular ultrasound (IVUS)-guided PCI at 12 months.
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based approach from within the left ventricle.
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
There were many opinions on the duration of dual antiplatelet therapy (DAPT) highlighted at the 2016 American College of ...
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the natural restoration of complex body parts as the synthetic graft is absorbed.
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic valve replacement (RDAVR) system for patients with severe aortic stenosis.